Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Legg Mason Keeps 'Buy' on Array Biopharma


Legg Mason raised the price target and reiterates the buy rating on Array Biopharma (ARRY).

Analyst John Woolford says the timing of an investigational new drug application is in line with expectations, and should allow for the initiation of a Phase I trial in Spring, 2004. He believes the Food and Drug Administration's acceptance of Array's ARRY-142886 cancer-drug application is an important step in Array's transformation into a clinical-stage therapeutics company, and demonstrates the efficiency of its drug delivery platform.

Woolford says potential upcoming catalysts include the initiation of a Phase I trial for MEK-142886, updates from ongoing collaborations, and new collaborations. He upped the $11 target to $13. He sees a 12 cents third-quarter loss, and a 10 cents fourth-quarter loss.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus